Stella Lymberis, MD

Engineer, Physician, Oncology Expert #radiationoncology #womenwhocurie #brachytherapy @AmericanBrachy @NYULH_RadOnc #StellaLymberis Tweets=MyOwn

[Stella Lymberis, MD @lymberis]

Fund Science! Support Cancer Research and all Research which furthers our understanding of the human condition - every once in a while we get amazing wins which make everything worth it! Congrats to all involved! A bright day for prostate cancer patients and those who love them and take care of them!

[Vincent Rajkumar @VincentRK]

Human scientific ingenuity and hardwork, not AI. Human clinical trialists and patients, not AI

The standing ovation at #ASCO26 for the unprecedented results in metastatic pancreatic cancer with daraxonrasib an oral RAS inhibitor is the result of research excellence and perseverance, and a witness to this.

AI won’t do the work or run the trials to make these advances. It can make the process easier in the future. But you still need human ingenuity and hard works to take a chemical and make it an effective approved medicine.

Institutions and companies must nurture the human talent. Academic medicine is bleeding talent. Leaders are appointed for pliability over excellence. With NIH funding of new investigators at an all time low, coupled with institutions and organizations extolling the efficiencies and prioritizing the virtues of AI, we are at risk slowing down our ability in drug development.

https://t.co/2YRwESyIuu

[Stella Lymberis, MD @lymberis]

Standing Ovation - doubling survival in pancreatic cancer with Ras/GTP Pathway - an incredible cooperative, multisite result, bringing our patients closer to cure!

[Dr. Lucky Tran @luckytran]

Incredible! Scientists receive a rare standing ovation after announcing that a new treatment can double the survival time for pancreatic cancer, the deadliest cancer once considered “undruggable.” When we fund and support science, we can achieve anything!

[Stella Lymberis, MD @lymberis]

@MAGAVoice Ειρήνη μην

[Stella Lymberis, MD @lymberis]

01101110 01000001 01101101 01101001 00100100 00100100 01101110 01101111 01110111

[Stella Lymberis, MD @lymberis]

NAMI https://t.co/bX9ZnMy9W5

[Stella Lymberis, MD @lymberis]

@piet_ost @DrewMoghanaki @NehaVapiwala @clau_carvajal_ @TylerSbrt @hletelier @_ShankarSiva @Mat_Guc @BarbaraJereczek beautiful paper

[Stella Lymberis, MD @lymberis]

@DrDimitrios but good for your soul

[Mukund Iyengar @mukundiyngr]

Every cancer drug you prescribe today
was once an NIH grant nobody noticed.

Pharma celebrates launches.

Few notice the 20–40 year runway behind that.

Gleevec took 41 years from NIH-funded discovery of the Philadelphia chromosome → FDA approval.

Behind every “breakthrough” sits a graveyard of failed attempts that made it possible.

Cut that lineage today,
the next Gleevec doesn’t arrive in 2067.

Funded science matters.

If someone says NIH funded science is inefficient,
show them this.

- - - - -
Source: NIH RePORTER · FDA · via @Jori_health
- - - - -

[Stella Lymberis, MD @lymberis]

@AmericanBrachy No more taping catheters for catheter to guidewire connections in brachytherapy which signal prior to treatment! Andy Ogilvy demonstrated a prototype device designed to verify HDR #brachytherapy channel connections to reduce incident of a frequent error. Congrats to Mahta McKee #innovation #safety #physics #brachytherapy https://t.co/WXGdwo1p1j

[Stella Lymberis, MD @lymberis]

Improving outcomes in gynecologic oncology requires addressing access to care and timely initiation of treatment. Interestingly, even though overall treatment time OTT is a well known factor correlated with cervical cancer outcomes, study of time of treatment initiation has not been well studied with no current standard existing in guidelines. Our study aimed to explore the demographic and clinical factors associated with delayed initiation of treatment for patients with cervical cancer treated with chemoradiation and brachytherapy and determine its impact on oncologic outcomes reviewing a 10 year database I created to report outcomes of patients with stage IB2 to IVA cervical cancer from 2009 to 2019.
Patients who initiated treatment within 8 weeks of diagnosis (early) were compared with those who initiated treatment after 8 weeks (delayed). We found that treatment initiation #delays were associated with a decrement in #survival. In this cohort, public hospital patients were more likely to have a favorable stage and improved survival than those from the private hospital but also were more likely to experience treatment initiation delays. Referral patterns and delays related to diagnostic workup were the most common factors contributing to delays in care establishment with
nearly 40% of patients with cervical cancer initiated treatment 8 weeks or later from the time of diagnosis. System factors, such as transferring care for oncologic treatment or diagnostic workup, were the most common reasons for delays. Each incremental increase in treatment initiation of 10 days was associated with worse overall survival. #cervicalCancer #timetotreatmentmatters #treatmentinitiationdelay #gynecologiccancer #survival #underserved #disparities Full paper at: https://t.co/LTx8HcBOsr

[Stella Lymberis, MD @lymberis]

Proud to be recognized by Castle Connolly as an Exceptional Women in Medicine, placing me among the top 2% of board-certified female physicians in the US. Thank you for your trust. It is truly an honor and privilege. #radiationoncology #cancerfighters #survivorship

[American Brachy @AmericanBrachy]

@ambrachy is honored to recognize @catherynyashar as the 2026 Ulrich Henschke Award recipient — the highest distinction in #brachytherapy. Join us in LA for on June 19th for her keynote lecture. #ABSbrachy2026 https://t.co/KNAaKzVwJ6. #thisisbrachytherapy #radonc

[Drew Moghanaki @DrewMoghanaki]

Tumors are “irradiated”, NOT RADIATED. Why? Because tumors don’t emit radiation. Thank you.

[Stella Lymberis, MD @lymberis]

Tonight Artificial Intelligence Healthcare Innovations December 2, 2025 All-star Panel on Healthcare AI. Live Zoom. Free Registration brought to you by Hellenic Medical Society at: https://t.co/lXs4LvFPsw

[American Brachy @AmericanBrachy]

Did you know, ABS has a podcast series called #BrachyBites! Tune in for expert insights and bite-sized discussions on #AllThingsBrachy. #brachytherapy #radonc #CancerCare #ThisisBrachytherapy
👉 Listen now: https://t.co/xQNntqFZe0

[Stella Lymberis, MD @lymberis]

@md_tien can get free access here: https://t.co/e8pEBO6e39

[Stella Lymberis, MD @lymberis]

Watch this informative journal club I hosted dissecting the latest trials in cervical cancer, KEYNOTE-A18 and INTERLACE. We discussed these neoadjuvant and immunotherapy approaches and put in context with MR image guided brachytherapy. Great job to Dr Krystin Bradley, ABS President Elect & Yale RO residents. Free access: https://t.co/yvVDR1kndP @AmericanBrachy #cervicalcancer #Brachytherapy #journalclub #cervicalcancer #cures #teachingthenextgeneration

[Stella Lymberis, MD @lymberis]

HACC and HMS AI in Medicine Event I helped organize feature Hellenic Experts in Medical AI which is revolutionizing the healthcare of the future.
https://t.co/iYt6N4YVp4